Egetis Therapeutics: Granted rolling NDA review based on currently available clinical data - Redeye
Redeye has a positive take on the news that Egetis has been granted a rolling NDA review based on currently available clinical data, and that the rolling NDA review will commence by the end of the year.
ANNONS
Redeye has a positive take on the news that Egetis has been granted a rolling NDA review based on currently available clinical data, and that the rolling NDA review will commence by the end of the year.
